Lv3
320 积分 2023-07-05 加入
Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis
3天前
已完结
Clinical feasibility of curative surgery after nab-paclitaxel plus gemcitabine-cisplatin chemotherapy in patients with locally advanced cholangiocarcinoma
3个月前
已完结
EASL-ILCA Clinical Practice Guidelines on the management of intrahepatic cholangiocarcinoma
3个月前
已完结
Neoadjuvant and adjuvant therapy for biliary tract cancer: Advances and limitations
3个月前
已完结
Unresectable biliary tract cancer: current and future systemic therapy
4个月前
已完结
Gallbladder Cancer
4个月前
已完结
Clinical treatment of cholangiocarcinoma: an updated comprehensive review
4个月前
已完结
Intrahepatic cholangiocarcinoma: Evolving strategies in management and treatment
4个月前
已完结
International Union of Angiology Position Statement on perioperative drug and hemostasis management in vascular surgery
4个月前
已关闭
Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma
6个月前
已完结
皖公网安备34019202002308
